MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) today welcomed the U.S. Food and Drug Administration’s (FDA) newly released draft guidance on the development of ...
MATAWAN, N.J. & SEOUL, South Korea--(BUSINESS WIRE)-- MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (“APUS” or the “Company”) (NYSE ...
MATAWAN, N.J. & EUGENE, Ore., October 14, 2025--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) ("Apimeds") today announced the expansion of the Apimeds ai ² Futures Lab program through ...
MATAWAN, N.J.--(BUSINESS WIRE)-- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Future Labs program by engaging graduate students from the ...
Apimeds Pharmaceuticals US, Inc. ( (APUS)) has shared an announcement. On May 4, 2026, Apimeds Pharmaceuticals US, Inc. appointed architect and urban designer Sungjoon Chae as Co-Chief Executive ...
Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) ...
Apimeds Pharmaceuticals is set to discuss a treatment for osteoarthritis using bee venom at a Type C meeting with the Food and Drug Administration. The pharmaceutical company, along with L kahi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results